Anastrozole

Generic Name: Anastrozole

Brand Names: Arimidex

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₉N_₅

CAS Number: 120511-73-1

Unique Ingredient Identifier: 2Z07MYW1AZ

Background: Anastrozole is a non-steroidal aromatase inhibitor (AI), similar to letrozole, used to decrease circulating estrogen levels in the treatment of postmenopausal women with estrogen-responsive breast cancer. Anastrozole is also related to exemestane, a steroidal AI, but its non-steroidal nature provides stark advantages including a lack of steroid-associated adverse effects such as weight gain and acne. Aromatase inhibitors, including anastrozole, have become endocrine drugs of choice in the treatment of postmenopausal breast cancer due to a more favourable efficacy and adverse effect profile as compared to earlier estrogen receptor modulators such as tamoxifen.

Anastrozole was first approved for use in the United States in 1995.

Indication: Anastrozole is indicated as adjunct therapy in the treatment of hormone receptor-positive early breast cancer in postmenopausal women, and as a first-line treatment for hormone receptor-positive (or hormone receptor-unknown) locally advanced or metastatic breast cancer in postmenopausal women. It may also be used in the treatment of advanced breast cancer in postmenopausal women who experience disease progression despite treatment with tamoxifen.

Associated Conditions: Advanced Breast Cancer, Invasive Early Breast Cancer, Locally Advanced Breast Cancer (LABC), Metastatic Breast Cancer, Stage I Breast Cancer

Associated Therapies: -

Clinical Trials

Pre-operative Hormonal Treatment for Hormone Receptor Positive Breast Cancer

Phase 2

Suspended

Conditions: Breast Cancer

Interventions: Drug: Tamoxifen
Drug: Anastrozole+Fulvestrant
Drug: Anastrozole

First Posted Date: 2008-08-20

Last Posted Date: 2021-01-22

Lead Sponsor: The Netherlands Cancer Institute

Target Recruit Count: 250

Registration Number: NCT00738777

Locations: 🇳🇱
UMC St. Radboud, Nijmegen, Netherlands
🇳🇱
NKI-AVL, Amsterdam, Netherlands
🇳🇱
Medisch Centrum Haaglanden, den Haag, ZH, Netherlands

and more 1 locations

A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer

Phase 2

Completed

Conditions: Metastatic Breast Cancer

Interventions: Biological: IMC-A12 (cixutumumab)
Drug: tamoxifen
Drug: Anastrozole
Drug: Letrozole
Drug: Exemestane
Drug: Fulvestrant

First Posted Date: 2008-08-06

Last Posted Date: 2018-06-06

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 93

Registration Number: NCT00728949

Locations: 🇺🇸
ImClone Investigational Site, Nashville, Tennessee, United States

Effect of Aromatase Inhibitor Therapy on Blood Vessel Function in Postmenopausal Women With Breast Cancer

Completed

Conditions: Breast Cancer

Interventions: Procedure: assessment of therapy complications
Drug: anastrozole
Drug: exemestane
Drug: letrozole

First Posted Date: 2008-07-22

Last Posted Date: 2024-01-02

Lead Sponsor: Mayo Clinic

Target Recruit Count: 109

Registration Number: NCT00719966

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Cyclophosphamide, Methotrexate, and Prednisolone With or Without Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer

Phase 2

Conditions: Breast Cancer

Interventions: Drug: anastrozole
Drug: cyclophosphamide
Drug: exemestane
Drug: letrozole
Drug: methotrexate
Drug: prednisolone

First Posted Date: 2008-06-02

Last Posted Date: 2009-06-17

Lead Sponsor: National Cancer Centre, Singapore

Target Recruit Count: 70

Registration Number: NCT00687648

Locations: 🇸🇬
National Cancer Centre - Singapore, Singapore, Singapore

Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor Therapy

Phase 3

Conditions: Breast Cancer

Interventions: Drug: anastrozole
Drug: fulvestrant
Other: placebo
Drug: lapatinib ditosylate
Drug: exemestane
Drug: letrozole

First Posted Date: 2008-06-02

Last Posted Date: 2013-08-26

Lead Sponsor: Gruppo Italiano Mammella (GIM)

Target Recruit Count: 396

Registration Number: NCT00688194

Locations: 🇮🇹
Federico II University Medical School, Naples, Italy

Cognitive Function in Older Women With Stage I, Stage II, or Stage III Breast Cancer Receiving Hormone Therapy

Completed

Conditions: Breast Cancer

Interventions: Drug: anastrozole
Drug: letrozole
Other: questionnaire administration
Procedure: cognitive assessment
Procedure: psychosocial assessment and care

First Posted Date: 2008-05-21

Last Posted Date: 2011-12-02

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 72

Registration Number: NCT00681928

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States

Estrogen in Postmenopausal Women With ER Positive Metastatic Breast Cancer After Failure of Sequential Endocrine Therapy

Phase 2

Terminated

Conditions: Breast Cancer
Neoplasms, Breast
Cancer of the Breast

Interventions: Drug: Estrace
Drug: Anastrozole

First Posted Date: 2008-04-18

Last Posted Date: 2017-04-12

Lead Sponsor: Georgetown University

Target Recruit Count: 11

Registration Number: NCT00661531

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Cooper Cancer Institute, Voorhees, New Jersey, United States
🇺🇸
Georgetown University Medical Center, Washington, District of Columbia, United States